TY - JOUR
TI - The Use of Norethisterone for the Treatment of Severe Uterine Bleeding in Adolescents: An Audit of Our Experience
AU - Papapanagiotou, I.K.
AU - Charamanta, M.
AU - Roidi, S.
AU - Al-Achmar, N.S.
AU - Soldatou, A.
AU - Michala, L.
JO - Journal of Pediatric and Adolescent Gynecology
PY - 2019
VL - 32
TODO - 6
SP - 596-599
PB - ELSEVIER SCIENCE INC 360 PARK AVE SOUTH, NEW YORK, NY 10010-1710 USA
SN - 1083-3188
TODO - 10.1016/j.jpag.2019.09.002
TODO - hemoglobin;  norethisterone;  norethisterone;  oral contraceptive agent, adolescent;  Article;  beta thalassemia;  blood transfusion;  body mass;  body weight;  child;  chronic kidney failure;  clinical article;  constipation;  controlled study;  disease duration;  disease severity;  drowsiness;  drug efficacy;  drug safety;  drug tolerability;  dysmenorrhea;  female;  headache;  hematocrit;  hemoglobin blood level;  human;  menarche;  menstruation;  nausea;  non insulin dependent diabetes mellitus;  personal experience;  priority journal;  prospective study;  tertiary care center;  uterus bicornis;  uterus bleeding;  vagina bleeding;  visual analog scale;  clinical audit;  treatment outcome;  uterus bleeding, Adolescent;  Child;  Contraceptives, Oral, Hormonal;  Female;  Humans;  Medical Audit;  Menarche;  Norethindrone;  Prospective Studies;  Treatment Outcome;  Uterine Hemorrhage
TODO - Study Objective: The purpose of this prospective study was to assess the effectiveness of norethisterone (NET) in the management of abnormal uterine bleeding (AUB) in adolescents in a tertiary care center. Design: This was a prospective audit focused on administering high doses of NET in female adolescents with complaints of AUB. Setting: We included female adolescents who presented to our Emergency Gynecological Department or Adolescent Gynecological Outpatient Department from October 2016 to January 2019. Participants: The study included 29 female adolescents aged 11-17 (mean, 13.14) years. Interventions: Patients were administered a daily dose of 10-30 mg, depending on the severity of the condition, bleeding duration, and patient weight. Main Outcome Measures: Cessation of vaginal bleeding. Results: Mean age at menarche of our patient sample was 11.4 years (range, 10.7-14 years). AUB presented at a mean time of 24.6 months after menarche (range, 0-79 months). Blood transfusion was deemed necessary in 9 patients. Bleeding stopped at a mean of 46.1 (range, 8-120) hours after onset of treatment with NET. No serious adverse events were reported with NET administration, with only 3 cases of minor side effects. Conclusion: The use of NET is an effective and reliable treatment option among adolescents for whom control of AUB is desired in the acute setting. © 2019 North American Society for Pediatric and Adolescent Gynecology
ER -